Micafungina Hikma (Micafungin)

Micafungin is an echinocandin antifungal used to treat serious Candida infections and to prevent infection in high‑risk transplant patients.

• Invasive candidiasis: effective treatment that clears bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: alleviates mucosal infection and promotes healing of esophageal lesions.
• Prophylaxis in hematopoietic stem cell transplant recipients: reduces the incidence of invasive Candida infections during the neutropenic phase.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a critical structural component of the fungal cell wall. By disrupting cell‑wall assembly, the drug weakens fungal integrity, causing osmotic instability and cell lysis while sparing human cells that lack this pathway.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature.
• Nausea: mild to moderate upset stomach.
• Headache: occasional throbbing pain.
• Elevated liver enzymes: mild increase in ALT/AST.
• Phlebitis at infusion site: irritation or redness.
• Diarrhea: loose stools.

Serious or Rare Side Effects

• Hepatotoxicity: significant liver injury with jaundice.
• Severe hypersensitivity: rash, angioedema, or anaphylaxis.
• Renal impairment: acute kidney injury.
• Hematologic abnormalities: neutropenia or thrombocytopenia.

When using Micafungin, clinicians should observe several precautionary measures to ensure patient safety.

• Assess liver function: monitor ALT, AST, bilirubin before and during therapy.
• Evaluate renal function: adjust use in patients with pre‑existing kidney disease.
• Monitor for hypersensitivity: discontinue if signs of severe allergic reaction appear.
• Use caution in neonates and pediatric patients: limited safety data available.
• Avoid concomitant use with strong CYP3A4 inducers: may reduce exposure.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Rifampin: strong inducer of hepatic enzymes that markedly reduces micafungin plasma levels.
• Cyclosporine: may increase micafungin exposure, raising risk of liver toxicity.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole, voriconazole): may alter micafungin metabolism, requiring monitoring.
• Immunosuppressants (e.g., tacrolimus): potential additive hepatotoxicity.
• Warfarin: possible effect on anticoagulation parameters; monitor INR.
• Concomitant nephrotoxic agents: increased risk of renal impairment.